Baxalta(BXLT)
Baxalta (Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound') is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. The company began its operation with a revenue of $6 billion, and is now a subsidiary of Takeda Pharmaceutical Company.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Adynovi | Rurioctocog alfa pegol | 2018-01-08 | ||
| Hyqvia | Human normal immunoglobulin | 2013-05-16 | — | |
| Rixubis | Nonacog gamma | 2014-12-19 | — | |
| Veyvondi | Vonicog alfa | 2018-08-31 |
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use